CD47 and neoplasm: Additionally, experiments with Bifidobacterium combined with anti‐CD47 immunotherapy in tumor‐bearing mouse models demonstrate that systemically administered Bifidobacterium can selectively accumulate in the TME, while local administration can trigger activation of the stimulator of interferon genes (STING) pathway, synergistically enhancing clinical responses to anti‐CD47 immunotherapy [209].